Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II...
Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II...
Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III
默沙東宣佈，加拿大藥物管理局已建議將WINREVAIR與標準肺動脈高壓療法聯合用於治療世界衛生組織第1組PAH和功能類別II或IIII的成年人進行報銷
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.
在美國和加拿大以外被稱爲默沙東的默沙東（紐約證券交易所代碼：MRK）宣佈，加拿大藥物管理局（CDA）已建議使用WINREVAIR（sotatercept）與標準肺動脈高壓（PAH）療法聯合使用世界衛生組織 [WHO] 第1組多環芳烴和功能類別（FC）II或III類的成人進行報銷。
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.
Sotatercept是加拿大第一種針對多環芳烴的激活素信號抑制劑療法，這是一種新的療法，其作用是改善促增殖和抗增殖信號之間的平衡，以調節多環芳烴患者的血管增殖。
